Antiretroviral therapy restores age-dependent loss of resting memory B cells in young HIV-Infected zambian children

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 5, 2014, Pages 505-509

  Rainwater Lovett, Kaitlin ^a,e   Nkamba, Hope C ^b   Mubiana Mbewe, Mwnagelwa ^c   Moore, Carolyn B ^c,d,f   Margolick, Joseph B ^a   Moss, William J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c Centre for Infectious Disease Research   (Zambia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV child; Immune reconstitution; Resting memory B cell

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; INFANT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTING MEMORY B CELL; SCHOOL CHILD; ZAMBIA;

AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD19; ANTIGENS, CD27; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; INFANT; LYMPHOCYTE SUBSETS; MALE; PROSPECTIVE STUDIES; RECEPTORS, COMPLEMENT 3D; ZAMBIA;

EID: 84897974526     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000074     Document Type: Conference Paper

References (29)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2012
2. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: A pooled analysis. Lancet. 2004;364:1236-1243
3. Prendergast A, Mphatswe W, Tudor-Williams G, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008;22:1333-1343
4. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899
5. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359: 2233-2244
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: Http://www.who.int/hiv/pub/guidelines/arv2013/en/index.html. Accessed July 1, 2013
7. Lane HC, Masur H, Edgar LC, et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309:453-458
8. Ghosh S, Feyen O, Jebran AF, et al. Memory B cell function in HIVinfected children-decreased memory B cells despite ART. Pediatr Res. 2009;66:185-190
9. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9:235-245
10. De Milito A., Morch C, Sonnerborg A, et al. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS. 2001;15:957-964
11. Buckner CM, Moir S, Ho J, et al. Characterization of plasmablasts in the blood of HIV-infected viremic individuals: Evidence for nonspecific immune activation. J Virol. 2013;87:5800-5811
12. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol. 2008;122:12-19
13. Nagase H, Agematsu K, Kitano K, et al. Mechanism of hypergammaglobulinemia by HIV infection: Circulating memory B-cell reduction with plasmacytosis. Clin Immunol. 2001;100:250-259
14. De Milito A., Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-2186
15. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS. 2005;19: 1947-1955
16. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008;197:572-579
17. Pensieroso S, Cagigi A, Palma P, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A. 2009;106: 7939-7944
18. Rainwater-Lovett K, Nkamba HC, Mubiana-Mbewe M, et al. Immunologic risk factors for early mortality after starting antiretroviral therapy in HIV-infected Zambian children. AIDS Res Hum Retroviruses. 2013;29: 479-487
19. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998; 188:1679-1689
20. Chong Y, Ikematsu H, Kikuchi K, et al. Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2004;20:219-226
21. DOrsogna LJ, Krueger RG, McKinnon EJ, et al. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS. 2007;21:1747-1752
22. Cagigi A, Palma P, Nilsson A, et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS. 2010;24:2075-2080
23. Titanji K, De MA, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108:1580-1587
24. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: Evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116: 5571-5579
25. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: An observational study. J Infect Dis. 2007;196:347-355
26. Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: Loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics. 2006;118:e315-e322
27. Iwajomo OH, Finn A, Moons P, et al. Deteriorating pneumococcalspecific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis. 2011;204:534-543
28. Rainwater-Lovett K, Nkamba HC, Mubiana-Mbewe M, et al. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities. J Infect Dis. 2013;208:1747-1755
29. WHO. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2010